Target intelligence / Profile preview

Hepatic uptake and clearance

01

Overview

Hepatic uptake and clearance refers to the complex physiological process by which the liver removes substances, including drugs, from the bloodstream. This vital pharmacokinetic process involves the coordinated action of various molecular entities, primarily drug transporters located on hepatocyte membranes and drug-metabolizing enzymes within hepatocytes. Substances are first taken up into liver cells (hepatocytes) by specific uptake transporters, such as Organic Anion Transporting Polypeptides (OATPs) and Organic Cation Transporters (OCTs). Once inside, they can be chemically modified by enzymes, notably the Cytochrome P450 (CYP) family, and subsequently excreted into bile via efflux transporters like Multidrug Resistance-Associated Proteins (MRPs), or returned to the bloodstream. This process is critical for determining a drug's bioavailability, half-life, and overall exposure in the body. Dysregulation of hepatic uptake and clearance, often due to genetic variations, liver disease, or drug-drug interactions, can lead to significant alterations in drug pharmacokinetics, potentially causing drug accumulation and toxicity or insufficient therapeutic effects.

Other names
Hepatic drug dispositionHepatic eliminationDrug clearance by the liver
02

Biological functions

The process by which the liver removes substances, including drugs, from the bloodstream. It involves both the uptake of substances into hepatocytes and their subsequent metabolism and/or excretion into bile or back into the blood. This process is crucial for drug pharmacokinetics, determining the concentration of drugs in the body and their duration of action.
03

Disease associations

Impairment of hepatic uptake and clearance can lead to altered drug pharmacokinetics, resulting in drug accumulation and potential toxicity, or reduced drug efficacy. Liver diseases, genetic polymorphisms in enzymes or transporters, and drug-drug interactions can significantly impact this process.
04

Safety considerations

Drug-drug interactions (DDIs) due to competition or modulation of hepatic transporters and metabolizing enzymes, leading to altered drug exposure and potential toxicity or lack of efficacy. Genetic polymorphisms in these components can also lead to inter-individual variability in drug response. Hepatotoxicity can occur if the liver's capacity for uptake, metabolism, or excretion is overwhelmed or impaired.

Beyond the preview

Go deeper on Hepatic uptake and clearance.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepatic uptake and clearance.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call